Immediate Impact
3 from Science/Nature 61 standout
Citing Papers
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
2023 Standout
Works of Sudipta Bhattacharya being referenced
DURATION-8 Randomized Controlled Trial 104-Week Results—Once-Weekly Exenatide (ExQW) plus Once-Daily Dapagliflozin (DAPA) vs. ExQW or DAPA Alone
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Sudipta Bhattacharya | 385 | 165 | 121 | 128 | 12 | 458 | |
| Masashi Hirayama | 341 | 187 | 106 | 164 | 18 | 428 | |
| Y. G. Kim | 424 | 223 | 74 | 143 | 7 | 483 | |
| Miguel Nasser Hissa | 435 | 200 | 91 | 174 | 16 | 487 | |
| Karla Bergerhoff | 361 | 168 | 69 | 114 | 12 | 522 | |
| Rebecca J. Hodge | 314 | 260 | 99 | 189 | 13 | 537 | |
| S Ciani | 313 | 123 | 114 | 185 | 9 | 420 | |
| Kasper Aaboe | 469 | 174 | 61 | 268 | 12 | 541 | |
| Signe Stensen | 427 | 233 | 45 | 267 | 21 | 558 | |
| Renate E. van Genugten | 315 | 106 | 45 | 111 | 14 | 414 | |
| Annett Keller | 388 | 119 | 67 | 106 | 7 | 442 |
All Works
Login with ORCID to disown or claim papers
Loading papers...